With the AI gold rush in full swing, Optomed has longer-term plans in place to capitalize on this trend with further diagnostic capabilities and algorithms for other offerings.
A bevy of recent research has hinted at the promising diagnostic power of the eye for diseases from Alzheimer’s to rare cancers. Though the device is only currently approved for AEYE Health’s DR algorithm, Optomed envisions other products as screening powerhouses capable of scanning for a wide variety of ailments.
“We are currently actively exploring opportunities with other AI teams and companies who are developing algorithms for, say, cardiovascular or neurological disorders, or other blinding diseases,” Ms. Piila said. “Our platform can integrate multiple different algorithms into the camera, and we can expand accordingly.”
For Ms. Piila, it all adds up to Optomed’s vision for an AI-powered future of disease detection and management where everybody wins. “Eventually, this device will save costs and time for the entire healthcare equation. It’s a win for the physician, for the patient, for the insurers, for everyone,” she explained. And if Optomed’s bet on this future with the Aurora EYE is successful, a win for the company behind it all will surely follow.
Hei @Sheikki . Tuo viimeinen kappale todella mielenkiintoinen, jossa puhutaan kameran käytöstä myös muiden sairauksien diagnosointiin. Onko Sheikillä tullut vastaan tutkimuksia, joissa Optomedin kameraa + AI on tällätavoin hyödynnetty? Tämä näytä pitkänaikavälin hankkeita, mutta mehän katsomme täällä pitkälle tulevaisuuteen ja jo seuraavia laajennuksia